Carbylan Therapeutics Company Profile (NASDAQ:CBYL)

Analyst Ratings

Consensus Ratings for Carbylan Therapeutics (NASDAQ:CBYL) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $7.95 (1,280.21% upside)

Analysts' Ratings History for Carbylan Therapeutics (NASDAQ:CBYL)
Show:
DateFirmActionRatingPrice TargetActions
4/18/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$9.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016WedbushReiterated RatingOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016Leerink SwannDowngradeOutperform -> Market Perform$15.00 -> $1.80View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015Northland SecuritiesReiterated RatingOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Carbylan Therapeutics (NASDAQ:CBYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/11/2015        
11/11/2015Q315($0.26)($0.19)$0.01 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.21)($0.37)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Carbylan Therapeutics (NASDAQ:CBYL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.24)($0.23)($0.24)
Q2 20162($0.27)($0.25)($0.26)
Q3 20162($0.29)($0.28)($0.29)
Q4 20161($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Carbylan Therapeutics (NASDAQ:CBYL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Carbylan Therapeutics (NASDAQ:CBYL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/30/2015David RenziCEOSell10,000$3.70$37,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2015Acmp Iv LlcMajor ShareholderBuy877,500$5.00$4,387,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2015Albert ChaDirectorBuy1,012,500$5.00$5,062,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Carbylan Therapeutics (NASDAQ:CBYL)
DateHeadline
07/22/16 11:14 AMCarbylan Therapeutics, Inc. (NASDAQ:CBYL): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 08:39 PMEquity Roundup: Stock Performance Focus on Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Press Telegraph
07/21/16 07:21 AMIs $10 Price Target Attainable For Carbylan Therapeutics, Inc. (NASDAQ:CBYL)? - Investor Newswire
07/19/16 08:29 PMCarbylan Therapeutics Incorporated (NASDAQ:CBYL) Shorts Decreased by 59.61% After Short Covering - Consumer Eagle
07/19/16 03:10 PMActive Moments in Stocks - Citigroup, (NYSE:C), Carbylan Therapeutics, (NASDAQ:CBYL) - Hot Stocks Point
07/18/16 08:07 AMActive Movers - HSBC Holdings, (NYSE:HSBC), Carbylan Therapeutics, (NASDAQ:CBYL) - Hot Stocks Point
07/17/16 02:54 PMCarbylan Therapeutics Incorporated (NASDAQ:CBYL) Sellers Increased By 1.49% Their Shorts - Press Telegraph
07/17/16 02:54 PMShares Moving Down on the Week: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Engelwood Daily
07/15/16 12:29 PMAnalyst Target and Average Rating Watch: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Press Telegraph
07/15/16 12:29 PMCarbylan Therapeutics, Inc. (NASDAQ:CBYL) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 12:29 PMTrading Performance and Target Watch for Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Press Telegraph
07/14/16 08:35 PMCarbylan Therapeutics Incorporated (NASDAQ:CBYL) Short Interest Increased By 1.49% - Consumer Eagle
07/14/16 08:35 PMStrong Sell Calls For Carbylan Therapeutics, Inc. (NASDAQ:CBYL) At 0 - Investor Newswire
07/13/16 11:13 AMCarbylan Therapeutics, Inc. (NASDAQ:CBYL) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/11/16 07:56 AMStock Rating Watch and Earnings Insight for Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Press Telegraph
07/10/16 02:59 PMCarbylan Therapeutics, Inc. (CBYL) Broker Price Targets For The Coming Week - Fiscal Standard
07/08/16 11:04 AMCan Carbylan Therapeutics, Inc. (NASDAQ:CBYL) Improve on the Earnings Front? - Engelwood Daily
07/08/16 11:04 AMCompany Stock Focus for Carbylan Therapeutics, Inc. (NASDAQ:CBYL): Which Way Will Shares Head? - Press Telegraph
07/07/16 10:57 AMNew Broker Ratings For Carbylan Therapeutics, Inc. (CBYL) - FTSE News
07/07/16 10:57 AMCarbylan Therapeutics, Inc. (NASDAQ:CBYL) Expected to Reach Highs Of $10 - Investor Newswire
07/03/16 02:57 PMAre Analysts Bearish Carbylan Therapeutics Inc (NASDAQ:CBYL) After Last Week? - Engelwood Daily
07/01/16 11:10 AMCovering the Bases on Carbylan Therapeutics, Inc. (NASDAQ:CBYL): Where is the Stock Going? - Press Telegraph
06/30/16 03:21 PMCarbylan Therapeutics Incorporated (NASDAQ:CBYL) Short Interest Increased By 1.49% - Press Telegraph
06/29/16 10:21 AMCarbylan Therapeutics, Inc. (NASDAQ:CBYL) Company Rating and Target Watch - Telanagana Press
06/29/16 10:21 AMRecently Issued Stock Ratings For Carbylan Therapeutics, Inc. (CBYL) - Fiscal Standard
06/28/16 03:13 PMCARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement -
06/28/16 02:26 PMPrice Target Highlight: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - News Oracle
06/27/16 07:43 AMShare Update and Earnings Review for Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Press Telegraph
06/26/16 08:14 AMCarbylan Therapeutics Incorporated (NASDAQ:CBYL) Shorted Shares Increased By 1.49% - Engelwood Daily
06/24/16 03:12 PMCarbylan Therapeutics, Inc. (NASDAQ:CBYL) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 03:12 PMPrice Target Update on Carbylan Therapeutics (NASDAQ:CBYL) - Trade Calls
06/24/16 10:55 AMCarbylan Therapeutics, Inc. (CBYL) Updated Price Targets - FTSE News
06/22/16 03:48 PMCARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhi -
06/22/16 03:12 PMStrong Buy Calls Count For Carbylan Therapeutics, Inc. (NASDAQ:CBYL) At 2 - Investor Newswire
06/22/16 03:00 PMCarbylan Therapeutics and KalVista Pharmaceuticals Conference Call to Discuss Proposed Transaction - [GlobeNewswire] - SALISBURY, United Kingdom and PALO ALTO, Calif., June 22, 2016-- KalVista Pharmaceuticals Ltd., a privately held biopharmaceutical company, and Carbylan Therapeutics, Inc., today announced conference call ...
06/19/16 02:58 PMCarbylan Therapeutics, Inc. (CBYL) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 02:59 PMStocks inside Analysts Spotlight: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) , Carbylan Therapeutics, Inc. (NASDAQ ... - Street Updates
06/17/16 05:04 AMCARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/16/16 08:27 PMAnalyst Buzz: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - News Oracle
06/16/16 03:06 PMCarbylan Therapeutics (CBYL) Enters Merger Agreement with Privately-Held KalVista
06/15/16 07:54 AMWhat should one expect from? - Carbylan Therapeutics, Inc. (NASDAQ:CBYL), Rovi Corporation (NASDAQ:ROVI) - Beacon Chronicle
06/15/16 07:54 AMCarbylan Therapeutics (CBYL) Enters Merger Agreement with Privately-Held KalVista - StreetInsider.com
06/15/16 06:53 AMCARBYLAN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material -
06/15/16 06:39 AMCarbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement - [at noodls] - --Transaction forms combined NASDAQ-listed biopharmaceutical company, focused on the discovery, development and commercialization of plasma kallikrein inhibitors for the treatment of hereditary angioedema ...
06/15/16 06:31 AM7:31 am Carbylan Therapeutics and KalVista Pharma enter definitive share purchase agreement pursuant to which KalVista will become the majority owners of co -
06/14/16 03:02 PMValuable Price Trends to Observe: Argos Therapeutics, Inc. (NASDAQ:ARGS) , Carbylan Therapeutics, Inc. (NASDAQ ... - Street Updates
06/14/16 07:23 AMAnalyst Recommended These Stocks for Investors: Carbylan Therapeutics, Inc. (NASDAQ:CBYL), Fairmount Santrol ... - Beacon Chronicle
06/11/16 11:19 AMHave a look at Analyst Actions: Carbylan Therapeutics, Inc. (NASDAQ:CBYL) , BioDelivery Sciences International, Inc ... - Street Updates
06/10/16 03:10 PMTrend Of Rating Given To Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Investor Newswire
06/09/16 10:32 AMCarbylan Therapeutics, Inc. (NASDAQ:CBYL) Stock Rises, Analysts: Hold Rating - iStreetWire

Social

About Carbylan Therapeutics

Carbylan Therapeutics logoCarbylan Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of combination therapies. The Company's focus is on the development of Hydros-TA, its intra-articular injectable product candidate to treat pain associated with osteoarthritis (OA) of the knee. The Hydros-TA is a cross-linked combination of low dose corticosteroid and hyaluronic acid viscosupplement, designed to provide OA pain relief through a single intra-articular injection. Its technology includes drug/device combination products under development based on chemically engineered polymer systems incorporating hyaluronic acid, a polysaccharide present in the human body. Hydros-TA utilizes crosslinking technology to deliver both short-term pain relief with a low dose corticosteroid triamcinolone acetonide (TA) and sustained pain relief from its hyaluronic acid viscosupplement. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CBYL
  • CUSIP:
Key Metrics:
  • Previous Close: $0.58
  • 50 Day Moving Average: $0.760
  • 200 Day Moving Average: $0.919
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $15.17M
  • Beta: 3.1
  • Current Year EPS Consensus Estimate: $-0.890 EPS
  • Next Year EPS Consensus Estimate: $-1.410 EPS
Additional Links:
Carbylan Therapeutics (NASDAQ:CBYL) Chart for Tuesday, July, 26, 2016